Evolving Treatment Landscape in Renal Cell Carcinoma

Dr. Voss and Dr. Serzan close the discussion by reflecting on the evolution of treatment for advanced renal cell carcinoma (RCC) and the expanding therapeutic options now available to patients. Dr. Voss highlights improvements in survival outcomes, response rates, and disease control, emphasizing how these advances have changed the goals of frontline treatment to include long-term benefit, quality of life, and treatment-free survival. Dr. Serzan underscores the importance of continued clinical research in advancing care for patients with RCC, including the development of new mechanisms of action, combination strategies, and innovative clinical trial designs. He encourages continued clinical trial participation as an important pathway for improving outcomes and changing standards of care. Looking ahead, the experts anticipate further developments across clear cell and non-clear cell RCC and across both frontline and refractory disease settings. Dr. Voss and Dr. Serzan conclude by emphasizing the increasingly dynamic treatment landscape and the importance of evidence-based, informed decision-making in clinical practice.